Cargando…

MDB-17. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA

Medulloblastoma (MB) is a common malignant pediatric brain tumor with significant heterogeneity among its four molecular subgroups WNT, SHH, Group 3 and 4. Group 3/4 MB are aggressive with a relatively poor prognosis indicating a critical need for novel therapeutic targets. Since the transcriptomic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caisova, Veronika, Rivero-Hinojosa, Samuel, Chintala, Navya, Lu, I-An, Huizhen, Zhang, Mochizuki, Aaron, Yang, Jianhua, Rood, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Medulloblastomas - MDB
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260109/ http://dx.doi.org/10.1093/neuonc/noad073.250

Ejemplares similares

MDB-42. UNCOVERING DYNAMIC CHANGES IN MEDULLOBLASTOMA ASSOCIATED VASCULATURE IN ZEBRAFISH
por: Morris, Elysse, et al.
Publicado: (2023)

MDB-03. DFMO AS A TREATMENT STRATEGY IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2023)

MDB-28. DEEP LEARNING-BASED PERSONALIZED SURVIVAL PREDICTION FOR MEDULLOBLASTOMA
por: Stefan, Sabina, et al.
Publicado: (2023)

MDB-40. TRANSCRIPTOME-BASED DRUG REPURPOSING IN GROUP 3 MEDULLOBLASTOMA
por: Doss, David, et al.
Publicado: (2023)

MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA
por: Saulnier, Olivier, et al.
Publicado: (2023)

MDB-38. COMPUTATIONAL DRUG SENSITIVITY PREDICTS MEDULLOBLASTOMA SUBGROUP-SPECIFIC THERAPEUTICS
por: Jermakowicz, Anna, et al.
Publicado: (2023)

MDB-41. TARGETING EPIGENETIC REGULATORS TO INHIBIT GROUP 3 MEDULLOBLASTOMA MIGRATION
por: Jangde, Nitish, et al.
Publicado: (2023)

MDB-01. ELUCIDATING THE ROLE OF THE BAIAP2-CDC42 INTERACTION MEDULLOBLASTOMA
por: Ruiz, Luz, et al.
Publicado: (2023)

MDB-29. MEDULLOBLASTOMA SUBGROUP-SPECIFIC CHROMATIN STATES REVEAL NOVEL THERAPEUTIC VULNERABILITIES
por: Tao, Ran, et al.
Publicado: (2023)

MDB-35. RECURRENT MEDULLOBLASTOMA A RARE COMPLETE RESPONSE IN EXTRA NEURAL DISEASE
por: Schwartz, Jonathan, et al.
Publicado: (2023)

MDB-15. CLINICAL CHARACTERISTICS AND OUTCOME OF CHILDHOOD LI-FRAUMENI SYNDROME MEDULLOBLASTOMA PATIENTS
por: Kolodziejczak, Anna, et al.
Publicado: (2023)

MDB-09. IMPACT OF PRDM6 ON CHROMATIN ACCESSIBILITY, GENE EXPRESSION, AND MEDULLOBLASTOMA FORMATION
por: Schmidt, Christin, et al.
Publicado: (2023)

MDB-10. EPIDEMIOLOGICAL PROFILE OF MEDULLOBLASTOMA IN MOROCCO: A 2-YEAR RETROSPECTIVE STUDY
por: Erefai, Ouassima, et al.
Publicado: (2023)

MDB-05. HUMAN FETAL CEREBELLAR CELL ATLAS INFORMS MEDULLOBLASTOMA ORIGIN AND ONCOGENESIS
por: Luo, Zaili, et al.
Publicado: (2023)

MDB-08. THYROID HORMONES INHIBIT MEDULLOBLASTOMA PROGRESSION THROUGH INDUCING TUMOR CELL DIFFERENTIATION
por: Yang, Zeng-jie, et al.
Publicado: (2023)

MDB-25. LARGE CELL/ANAPLASTIC MEDULLOBLASTOMA REPRESENTS MORE THAN ONE DISEASE ENTITY
por: Krause, Katharina, et al.
Publicado: (2023)

MDB-18. MOLECULARLY-DEFINED MEDULLOBLASTOMA: POPULATION-LEVEL PATTERNS IN THE UNITED STATES, 2018-2019
por: Ostrom, Quinn T, et al.
Publicado: (2023)

MDB-31. PRELIMINARY STUDY ON BIOLOGICAL SIGNIFICANCE OF WTX G435D MUTATION IN MEDULLOBLASTOMA
por: Hu, Yuanjun, et al.
Publicado: (2023)

MDB-11. AN ONLINE CALCULATOR USING MACHINE LEARNING FOR PREDICTION OF SURVIVAL IN PEDIATRIC PATIENTS WITH MEDULLOBLASTOMA
por: Kuo, Cathleen, et al.
Publicado: (2023)

MDB-27. A PRO-DRUG OF TRIPTOLIDE IN CLINICAL DEVELOPMENT ATTENUATES HIGH-RISK MEDULLOBLASTOMA GROWTH
por: Rodriguez-Blanco, Jezabel, et al.
Publicado: (2023)

MDB-30. IDENTIFICATION AND CHARACTERIZATION OF NOVEL TRANSCRIBED ULTRACONSERVED REGIONS AS LONG NON-CODING RNAS IN MEDULLOBLASTOMA
por: Hudson, Kadie, et al.
Publicado: (2023)

MDB-06. PLASMA MEMBRANE PROFILING REVEALS A TARGETABLE CELL-SURFACE PHENOTYPE OF WNT-MEDULLOBLASTOMA
por: Taylor, Jessica T, et al.
Publicado: (2023)

MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023)

MDB-33. REST AND USP37 CONTROL THE MTORC1-AUTOPHAGY AXIS IN MEDULLOBLASTOMA BY REGULATING RAPTOR DEGRADATION
por: Cheng, Donghang, et al.
Publicado: (2023)

MDB-34. “INDUCING IRON IMBALANCE BY TARGETING THE ABCB7/GPX4 AXIS ACCELERATES FERROPTOSIS IN MEDULLOBLASTOMA”
por: Kanchan, Ranjana, et al.
Publicado: (2023)

MDB-19. MULTIOMIC PROFILING OF MEDULLOBLASTOMA REVEALS SUBTYPE-SPECIFIC TARGETABLE ALTERATIONS AT THE PROTEOME AND N-GLYCAN LEVEL
por: Godbole, Shweta, et al.
Publicado: (2023)

MDB-20. IMPROVING THE PERSISTENCE OF CAR T CELLS AGAINST GROUP 3 MEDULLOBLASTOMAS VIA EPIGENETIC REGULATION OF EXHAUSTION
por: Dukes, Meghan, et al.
Publicado: (2023)

MDB-32. TRANSLATION OF NON-CANONICAL OPEN READING FRAMES AS A CANCER CELL SURVIVAL MECHANISM IN CHILDHOOD MEDULLOBLASTOMA
por: Hofman, Damon, et al.
Publicado: (2023)

MDB-44. A TRANSFER LEARNING APPROACH FOR AUTOMATIC SEGMENTATION OF TUMOR SUB-COMPARTMENTS AND TUMOR HABITAT IN PEDIATRIC MEDULLOBLASTOMA
por: Bareja, Rohan, et al.
Publicado: (2023)

MDB-14. MULTI-OMICS OF HUMAN MEDULLOBLASTOMAS AND GENETIC LINEAGE TRACING IN VIVO IDENTIFY REGULATORS OF STEM-CELL MAINTENANCE
por: Yu, Bohyeon, et al.
Publicado: (2023)

MDB-26. CDK8 IS AN ONCOGENE IN GROUP 3 MEDULLOBLASTOMA THAT IMPACTS PROTEIN TRANSLATION BY REGULATING THE TRANSCRIPTIONAL ACTIVITY OF RIBOSOMAL GENES
por: Wang, Dong, et al.
Publicado: (2023)

MDB-12. TRANS-SPECIES ANALYSIS OF REPLICATION-REPAIR DEFICIENT (RRD) MEDULLOBLASTOMA AND RESPONSE TO IMMUNE-CHECKPOINT INHIBITION: AN IRRDC REPORT
por: Das, Anirban, et al.
Publicado: (2023)

MDB-23. ELP1 GERMLINE DEFICIENCY SENSITIZES THE GRANULE NEURON LINEAGE TO SHH MEDULLOBLASTOMA AND EXPOSES NOVEL THERAPEUTIC VULNERABILITIES
por: Garcia-Lopez, Jesus, et al.
Publicado: (2023)

MDB-02. NUCLEAR ENVELOPE PHOSPHATASE CTDNEP1 MUTATIONS POTENTIATE AGGRESSIVE MEDULLOBLASTOMA BY TRIGGERING MYC ACTIVATION AND GENOMIC INSTABILITY
por: Lu, Richard, et al.
Publicado: (2023)

MDB-36. SONIDEGIB, GANT61, AND VELIPARIB TREATMENT BOTH ALONE AND IN COMBINATION INCREASES RADIATION SENSITIVITY IN PEDIATRIC SONIC HEDGEHOG MEDULLOBLASTOMA
por: Price, Laura, et al.
Publicado: (2023)

MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS
por: Qadeer, Zulekha, et al.
Publicado: (2023)

MDB-39. ASSESSMENT OF MEDULLOBLASTOMA PATIENTS THROUGH MONITORING EXTRACELLULAR VESICLES VIA SURFACE-ENHANCED RAMAN SPECTROSCOPY COMBINED WITH MACHINE LEARNING
por: Mata, Carolina del Real, et al.
Publicado: (2023)

MDB-45. SELECTIVE B7-H3 INHIBITORS NI1 AND NI4 REDUCE AGGRESSIVENESS OF GROUP 3 MEDULLOBLASTOMA
por: Krishnan, Prakadeeswari Gopala, et al.
Publicado: (2023)

MDB-04. SINGLE-CELL TRANSCRIPTOMIC ANALYSIS REVEALS DISTINCT GENOMIC LANDSCAPES, CELL TRAJECTORIES, AND TUMOUR-MICROENVIRONMENT INTERACTIONS IN FOUR SUBTYPES OF MEDULLOBLASTOMA
por: Ruchiy, Yana, et al.
Publicado: (2023)

MDB-13. CURRENT STATUS OF DIAGNOSIS AND TREATMENT FOR HIGH-RISK STAGE M2/M3 NON-WNT SUBTYPES MEDULLOBLASTOMA IN SOUTH CHINA
por: Cai, Linbo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2g6p042ddf15lk4cevpji4b3ch